Fangfei Qian
Overview
Explore the profile of Fangfei Qian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang H, Li Y, Wang Y, Zou B, Chen Y, Zhang Y, et al.
Transl Lung Cancer Res
. 2024 Aug;
13(7):1672-1684.
PMID: 39118889
Background: Kirsten rat sarcoma homolog () mutations are one of the key drivers in non-small cell lung cancer (NSCLC) and FDA-approved specific inhibitors of -G12C mutation are available clinically. However,...
2.
Zhang Y, Sun B, Yu Y, Lu J, Lou Y, Qian F, et al.
NPJ Precis Oncol
. 2024 Feb;
8(1):50.
PMID: 38409480
This research explores the potential of multimodal fusion for the differential diagnosis of early-stage lung adenocarcinoma (LUAD) (tumor sizes < 2 cm). It combines liquid biopsy biomarkers, specifically extracellular vesicle...
3.
Lu J, Han B, Zhang B, Zou B, Hu M, Liu H, et al.
J Control Release
. 2023 Aug;
362:197-209.
PMID: 37648084
Nanoplatform-based drug delivery plays an important role in clinical practice. Polymeric micellar (Pm) nanocarriers have been demonstrated to reduce the toxicity of paclitaxel in rats and non-small cell lung cancer...
4.
Zhang W, Wang J, Wang Q, Cheng Y, Yang L, Li Y, et al.
Lung Cancer
. 2023 Aug;
184:107353.
PMID: 37647728
Objective: Immune monotherapy as second-line treatment confers only modest survival benefit on non-small cell lung cancer (NSCLC) patients with no mutated driver genes, necessitating combination treatment strategies. This phase Ib...
5.
Li Y, Jiang H, Qian F, Chen Y, Zhou W, Zhang Y, et al.
Front Immunol
. 2023 Jun;
14:1161718.
PMID: 37266427
Introduction: Platinum-based chemotherapy is still the standard of care for Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients after developing EGFR-TKI resistance. However, no study focusing...
6.
Zhang Y, Qian F, Teng J, Wang H, Yu H, Chen Q, et al.
Lung Cancer
. 2023 Jun;
181:107262.
PMID: 37263180
Objective: The present study, CLUS version 2.0, was conducted to evaluate the performance of new techniques in improving the implementation of lung cancer screening and to validate the efficacy of...
7.
Zhang W, Deng P, Kong T, Zhang B, Qian F, Dong Y, et al.
Lung Cancer
. 2022 Sep;
173:43-48.
PMID: 36116169
Introduction: Extensive stage small cell lung cancer (ES-SCLC) is associated with poor prognosis. Recently, anlotinib has demonstrated significant clinical activity as a third-line or further on treatment. This study aimed...
8.
Li Y, Wang Y, Zhou W, Chen Y, Lou Y, Qian F, et al.
Thorac Cancer
. 2022 Sep;
13(19):2711-2722.
PMID: 36054506
Background: Small cell lung cancer (SCLC) is the most malignant and common form of neuroendocrine lung cancer with pure (P-SCLC) and combined subtypes (C-SCLC). However, little is known about the...
9.
Wang Y, Chen Y, Yang Z, Qian F, Hu M, Lu J, et al.
Ann Surg Oncol
. 2022 May;
29(9):5666-5678.
PMID: 35543906
Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare high-grade neuroendocrine carcinoma of the lung. Little is known about the differences between the pure and combined LCNEC subtypes, and thus...
10.
Yang Z, Chen Y, Wang Y, Hu M, Qian F, Zhang Y, et al.
Front Immunol
. 2022 Mar;
13:807575.
PMID: 35237263
Objective: Several trials have shown that pembrolizumab plus chemotherapy was more effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy monotherapy. However, whether pembrolizumab plus chemotherapy is still...